RxDoctor Payments Data

Avie Grunspan, MD

Sleep Medicine · San Antonio, TXNPI 1881695542

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,704 of the $3,142 with a category attached, or 86.1%. 22 manufacturers reported payments, led by Harmony Biosciences LLC at 39.3% of the total. Reporting peaked in 2023 at $829 and has fallen 72.9% since, to $225 in 2025.

$3,142in general payments, 2019–2025

Across 131 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$1K
  • Jazz Pharmaceuticals Inc.$494
  • Avadel CNS Pharmaceuticals, LLC$319
  • Regeneron Healthcare Solutions, Inc.$163
  • Fisher & Paykel Healthcare Inc$161
  • Axsome Therapeutics, Inc.$122
  • plus $648 from 16 others

What the payments were for

  • Consulting fees$2006%
  • Food & beverage$2,70486%
  • Education$2388%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,142 in reported general payments places this provider in the 65th percentile of 112 sleep medicine providers in Texas.

See all sleep medicine providers in Texas

Medicare billing

Part B allowed, 2024
$88,553
Medicare patients
637
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HorizantGabapentin Enacarbil16$11,214
DayvigoLemborexant11$3,655
Pramipexole DihydrochloridePramipexole Di-Hcl57$868
Modafinil16$622
Zolpidem Tartrate109$542
Gabapentin94$528
Ropinirole Hcl29$361
Estazolam12$215
Clonazepam53$179
Trazodone Hcl26$124
Sertraline Hcl12$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arbor Pharmaceuticals, Inc.Horizant$23$11,21416 claims
Eisai Inc.Dayvigo$29$3,65511 claims
Almatica Pharma LLCSertraline Hcl$40$9912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 sleep medicine providers in Texas.

Other sleep medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →